USC Vice President of Research Randolph Hall, left, joins Paul Aisen, director of the USC Alzheimer’s Therapeutic Research Institute, during the second annual partnership meeting, held Jan. 26-27 in San Diego.

The USC Alzheimer’s Therapeutic Research Institute (USC ATRI) held its second annual Partnership Meeting in San Diego recently.

The meeting, which was attended by 125 clinical trial protocol investigators and other trial staff who work closely with USC ATRI, brought together top researchers from around the country to collaborate and discuss methods for finding effective treatments and ultimately, a cure for Alzheimer’s disease (AD).

The event included a reception and dinner at the U.S. Grant Hotel on Jan. 26, followed by the Partnership Meeting on Jan. 27 at the Westin San Diego.

Paul Aisen, MD, professor of neurology and director and founder of USC ATRI at the Keck School of Medicine of USC, presented and spoke about his vision for the organization, which includes developing and implementing innovative trial designs and research strategies that incorporate the sharing of data, software and instruments across the AD community.

Others presenters included Reisa Sperling, MD, MMSc, from Harvard Medical School; Paul Newhouse, MD, from Vanderbilt University; and Jeffrey Cummings, MD, ScD, of the Global Alzheimer’s Platform Foundation.

Since its founding in June 2015, USC ATRI has grown from a team of 30 to more than 100 faculty and staff. For more information, go to https://keck2.usc.edu/atri/.